Shanghai, China, 25 March 2025 — Recently, 4C Medical Technologies, Inc. (4C Medical), a strategic partner of MicroPort® CardioFlow, announced the closing of its Series D financing round, resulting in gross proceeds of up to $175 million, led by Boston Scientific Corporation, with participation from both new and existing shareholders. The financing will be utilized to accelerate the clinical development and commercialization of the AltaValve™ System, the company's next generation transcatheter mitral valve replacement (TMVR) technology.
4C Medical is a medical device company dedicated to advancing minimally invasive therapies for structural heart disease, particularly in the areas of mitral and tricuspid valve regurgitation. Previously, MicroPort® CardioFlow made several rounds of investments in 4C Medical and holds exclusive commercial rights for AltaValve™ System in Mainland China, Hong Kong, Macau, and Taiwan.
Mitral regurgitation (MR) is the most common valvular heart disease, and if untreated, can lead to heart failure, arrhythmias, and even death. Current treatments include drug management, open surgical repair or replacement, and transcatheter edge-to-edge repair (TEER). However, for patients at high surgical risk, with severe mitral annular calcification, or complex heart anatomy, traditional treatments may not provide an effective or long-term solution.
The AltaValve™ System is the only fully retrievable transcatheter mitral valve system with a low outer diameter that passes through the atrial septum. Once launched, it is expected to be the first MR treatment that requires only atrial fixation. The innovative design overcomes the anchoring challenges of current TMVR technologies, protects the patient’s heart structure during the procedure, minimizes the risk of left ventricular outflow tract obstruction or injury, and improves clinical outcomes.
4C Medical is currently conducting a global pivotal trial ATLAS (A Transseptal Left Atrial System for Treatment of Mitral Regurgitation) in the U.S. and Europe. The ATLAS pivotal trial is designed to assess the safety and effectiveness of the AltaValve™ System in treating patients with moderate-to-severe or severe MR who are unsuitable for surgery or TEER.The trial includes two separate non-randomized cohorts: moderate/severe mitral annular calcification (MAC) cohort and primary cohort that will include patients with no or mild MAC. The success of this trial is crucial for AltaValve™ System’s approval and market launch and will influence the broader field of TMVR technology.
Guoming Chen, Chairman of MicroPort® CardioFlow, stated, "As the largest shareholder before this round, we have witnessed 4C Medical’s growth from a concept to a leader in the global cardiovascular market. This financing is an important milestone, not only bringing hope to global MR patients but also validating MicroPort® CardioFlow’s long-term investment strategy in 4C Medical — supporting disruptive innovative enterprises and driving continuous advancements in structural heart disease treatments. With the growing demand for safe, effective, and minimally invasive treatments, TMVR is set to become a major treatment option. 4C Medical is well-positioned to lead in this field, and we will continue to support its growth, helping to improve patient lives worldwide."
About MicroPort® CardioFlow
Founded in 2015, MicroPort® CardioFlow (MicroPort® CardioFlow Medtech Corporation; HKEX: 02160) is a leading medical device company focusing on research, development and commercialization of innovative transcatheter and surgical solutions for structural heart disease.
MicroPort® CardioFlow’s self-developed transcatheter aortic valve implantation series products are successfully used in more than 700 core hospitals worldwide. In addition, MicroPort® CardioFlow has established a strategic Research and Development pipeline covering TAVI (transcatheter aortic valve treatment) products, left atrial appendage closure systems, transcatheter mitral valve treatment products, transcatheter tricuspid valve treatment products, and surgical accessories through in-house development and collaboration with global partners. MicroPort® CardioFlow is committed to providing total solutions for structural heart diseases, delivering high-quality therapeutic solutions to patients and physicians across the globe.
More information is available at: https://en.cardioflowmedtech.com/